---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-25-000044"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:19:16.812624+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio Q1 net product revenue ~$16.5M (+129% QoQ); submits sBLA for NMIBC papillary disease

## Summary
- Q1 2025 net product revenue ~$16.5M (+129% QoQ from $7.2M in Q4 2024).
- Unit sales volume in Q1 2025 grew 150% QoQ exceeding FY2024 total; March up 69% MoM.
- Submitted sBLA to FDA for ANKTIVA+BCG in BCG-unresponsive NMIBC papillary disease; 93% cystectomy avoidance at 20.7 months.
- Submitted Expanded Access Protocol (EAP) for ANKTIVA to treat lymphopenia after RMAT designation in Q1.

## SEC filing metadata
- accession: 0001326110-25-000044
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611025000044/0001326110-25-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611025000044/ibrx-20250415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-25-000044
- JSON: https://secwatch.observer/filing/0001326110-25-000044.json
- Plain text: https://secwatch.observer/filing/0001326110-25-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.